__NUXT_JSONP__("/drugs/Feladilimab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.",fdaUniiCode:"OUP4QB2A3R",identifier:"C126804",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C141145"],synonyms:["Anti-ICOS Agonist Antibody GSK3359609","FELADILIMAB",a,"GSK3359609"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FFeladilimab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Feladilimab","","2021-10-30T13:30:52.943Z")));